Article thumbnail

Identification of early molecular markers for breast cancer

By Céline Kretschmer, Anja Sterner-Kock, Friederike Siedentopf, Winfried Schoenegg, Peter M Schlag and Wolfgang Kemmner
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2001). AF: The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med
  2. (2001). AF: The role of osteopontin in breast cancer: clinical and experimental studies.
  3. (2007). al: Comparison of gene expression data from human and mouse breast cancers: identification of a conserved breast tumor gene set.
  4. (1997). al: Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med
  5. (2007). Alani RM: Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS ONE
  6. (2007). Alves J: FOXM1, a typical proliferation-associated transcription factor. Biol Chem
  7. (1995). AP: The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta
  8. (2007). Bandyopadhyay D: MUC1: a target molecule for cancer therapy. Cancer Biol Ther
  9. (2010). et al: Analysis of cell type-specific expression of CK1 epsilon in various tissues of young adult BALB/c Mice and in mammary tumors of SV40 T-Agtransgenic mice.
  10. (2008). et al: Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res
  11. (2003). et al: Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res
  12. (2009). et al: Detection of different tumor growth kinetics in single transgenic mice with oncogene-induced mammary carcinomas by flat-panel volume computed tomography.
  13. (2006). et al: Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
  14. (2009). et al: Ductal carcinoma in situ: state of the science and roadmap to advance the field.
  15. (2004). et al: Genomewide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis.
  16. (2000). et al: Identification of factors interacting with hMSH2 in the fetal liver utilizing the yeast two-hybrid system.
  17. (2007). et al: Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene
  18. (2002). et al: Microcalcifications of breast cancer and atypical cystic lobules associated with infiltration of foam cells expressing osteopontin. Virchows Arch
  19. (2005). et al: Molecular imaging of breast cancer in a transgene mouse model. Chirurgisches Forum
  20. (2003). et al: NuSAP, a novel microtubule-associated protein involved in mitotic spindle organization.
  21. (1998). et al: Osteopontin expression in a group of lymph node negative breast cancer patients.
  22. (2003). et al: The case for early detection. Nat Rev Cancer
  23. (2007). et al: The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology
  24. (2008). et al: Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer.
  25. (2006). et al: X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell
  26. (2001). Expression of epithelial mucins
  27. (2005). Follettie MT: Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res
  28. (2003). Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA
  29. (2000). Genetically engineered mouse models of mammary intraepithelial neoplasia.
  30. (2004). Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia
  31. (1986). Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase. Mol Cell Biol
  32. (1994). JT: Identification of genes expressed in premalignant breast disease by microscopy-directed cloning.
  33. (2008). Kuerer HM: The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer
  34. (2008). Kuo PC: Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev
  35. (2004). Liskay RM: EXO1-A multi-tasking eukaryotic nuclease. DNA Repair (Amst)
  36. (2008). MV: Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS ONE
  37. (2008). Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res
  38. (2006). Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res
  39. (2008). Recent advances and current controversies in the management of DCIS of the breast. Cancer Treat Rev
  40. (2002). Roche PC: Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR. Breast Cancer Res Treat
  41. (2005). S: What makes MUC1 a tumor antigen? Tumour Biol
  42. (1983). Sato A: Regulation of ribonucleotide reductase activity in mammalian cells. Mol Cell Biochem
  43. (2001). Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
  44. (2009). Silver A: The opposing roles of Wnt-5a in cancer.
  45. (2003). SJ: MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene
  46. (2007). The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev
  47. (2000). W: A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland. Oncogene